12.85M
Market cap
Current P/E
Forward P/E

About

Health care
Sector
Biotechnology
Industry

Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease.

Similar securities

Based on sector and market capitalization

Report issue